Jason Adhikaree

Has grant

Clinical Associate Professor in Oncology

University of Nottingham

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jason Adhikaree is a Clinical Associate Professor in Oncology at the University of Nottingham, UK. His research primarily focuses on treatment outcomes in non-small cell lung cancer and glioblastoma, including the use of ctDNA and immunotherapy strategies. Recent publications include studies on neo-adjuvant treatments and barriers to effective therapies in lung cancer patients.

Recent Grants

Grant: Close

Enhanced dendritic cell immunology for Glioblastoma

Open Date: 2015-01-01

Close Date: 2018-12-01

Grant: Close

Enhanced Dendritic Cell Immunology for Glioblastoma

Open Date: 2015-01-01

Close Date: 2017-12-31

Grant: Close

Academic Clinical Fellowship

Open Date: 2012-08-01

Close Date: 2015-01-01

Articles (9)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2020

Year:

2020

Collaborators (2)

Ehsan Ghorani

Associate Professor in Cancer Immunology

Imperial College London

UNITED KINGDOM

View details

Philip Badman

Imperial College London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jason Adhikaree

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (9)

69 Real world experience of treatment outcomes comparing ctDNA to tissue NGS in patients with advanced non-small cell lung cancer

86 Real World Outcomes of Patients Receiving Neoadjuvant Treatment for Non-Small Cell Lung Cancer

91 Identifying potential barriers to receipt of neo-adjuvant chemo-immunotherapy (NACT-IO) in resectable stage 2 and 3 lung cancer patients - Nottingham's experience

204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design

79 The routine use of Granulocyte-colony stimulating factor (G-CSF) with chemo-immunotherapy does not affect clinical outcomes in lung adenocarcinoma

A Rapidly Enlarging Skin Lump.

REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.

Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma.

Collaborators (2)

Ehsan Ghorani

Philip Badman

Make your next move.